HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NPF promotes Knowles, adds board members

This article was originally published in The Tan Sheet

Executive Summary

The Natural Products Foundation names Deborah Knowles executive director and elects six board members to three-year terms. The nonprofit linked to the Natural Products Association said June 3 Knowles, with NPF since 2008 when it merged with the Dietary Supplement Education Alliance, was promoted from the development director post to replace former Executive Director Tracy Taylor ( 1"The Tan Sheet" June 30, 2008). NPF June 1 announced board members including Carilyn Anderson, sales executive for Arlington Heights, Ill.-based Carlson Labs; Jane Drinkwalter, VP of sales for Irvine, Calif.-based Vitamer Labs; Peter Hafermann, president of Carrollton, Texas-based Alix Technologies; David Matteson, president of Seattle-based Early Edge Solutions; J.D. Weir, CEO of Scottsdale, Ariz.-based Primus Pharmaceuticals; and Bruce Worley Jr., director of field sales at East Hampton, Conn.-based Humphreys Pharmacal

You may also be interested in...



DSEA Becomes Tax Exempt With Move To Natural Products Foundation

Contributions to support the Dietary Supplement Education Alliance's goals could increase with the group's merger with the Natural Products Foundation, a tax-exempt charitable organization

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS135100

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel